Please login to the form below

Not currently logged in
Email:
Password:

etanercept

This page shows the latest etanercept news and features for those working in and with pharma, biotech and healthcare.

Amgen raises forecasts after closing $13.4bn Otezla deal

Amgen raises forecasts after closing $13.4bn Otezla deal

Otezla slots into Amgen’s existing psoriasis and anti-inflammatory product range, which includes Enbrel (etanercept) and Amgevita, its biosimilar of AbbVie’s Humira (adalimumab) which is approved and already available

Latest news

More from news
Approximately 7 fully matching, plus 92 partially matching documents found.

Latest Intelligence

  • The tipping point The tipping point

    Driving disparity. If we look across Europe at biosimilar penetration, even the recently launched infliximab and etanercept biosimilars show highly variable uptake between markets.

  • Deal Watch October 2016 Deal Watch October 2016

    For example Samsung Bioepis also based in South Korea, signed a deal with Merck &Co in 2013 for a range of biosimilars including infliximab, trastuzumab and etanercept (Amgen's Enbrel with ... The FDA accepted the Biologics Licence Application for

  • Cost containment and the German market Cost containment and the German market

    The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    drugs Humira (adalimumab) and Enbrel (etanercept) - last year's first and third best selling drugs respectively - are also in the biosimilar firing line.

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    255. Coherus Biosciences / Baxter International. Licence. Etanercept biosimilar for rhematoid arthritis.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

  • Infographic: RA Perceptions

    expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’

  • Brand leaders in RA will lose market share, predict rheumatologists

    leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics